medigraphic.com
Colegio de Medicina Interna de México.

2020, Número 3

<< Anterior Siguiente >>

Med Int Mex 2020; 36 (3)


Manifestaciones cardiológicas en pacientes con COVID-19

Clemente-Herrera A, Sánchez-De la Torre EJ, Enríquez-Contreras JM

Idioma: Español
Referencias bibliográficas: 33
Paginas: 357-364
Archivo PDF: 201.06 Kb.


RESUMEN

En diciembre de 2019 se reportaron varios casos de neumonía, cuyo agente causal sería denominado SARS-CoV-2 provocando la enfermedad por coronavirus (COVID- 19). A pesar de que el cuadro sintomático principal es respiratorio, se han reportado afectaciones en otros sistemas, el cardiovascular es uno de los principales. Las afectaciones cardiovasculares, que son menos comunes y condicionadas por un proceso fisiopatológico de inflamación sistémica, están representadas principalmente por daño miocárdico agudo, seguido de arritmias, mismas que no son especificadas por los autores. También se han descrito choque cardiogénico, insuficiencia cardiaca, tromboembolismo venoso o sistémico y síndrome coronario agudo; todo esto en poblaciones en las que predomina el sexo masculino, mayor edad y su asociación con peor pronóstico. Es necesario comprender las manifestaciones cardiológicas por medio de investigaciones que nos permitan conocer también su relación con otros factores de riesgo y las repercusiones a mediano y largo plazo, con el fin de no solo tener la sospecha clínica oportuna en estos pacientes, sino de ofrecer atención y manejo apropiados e integrales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Coronavirus Disease 2019 (COVID- 19); Situation Report - 92 [Internet]. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/ situation-reports/20200421-sitrep-92-covid-19. pdf?sfvrsn=38e6b06d_4.

  2. Garcia C, Maguiña C, Gutierrez R. El síndrome respiratorio agudo severo. Rev Med Hered. 2003;14(2):89–93.

  3. Paules C, Marston H, Fauci A. Coronavirus infections— more than just the common cold. JAMA 2020;323(February): 707-8. doi:10.1001/jama.2020.0757.

  4. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020;26(April):450-5.

  5. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiology 2020;1-10. doi:10.1001/jamacardio. 2020.1286

  6. Hanff T, Harhay M, Brown T, Cohen J, Mohareb A. Is there an association between COVID-19 mortality and the reninangiotensin system—a call for epidemiologic investigations. Clin Infect Dis 2020;1-21. https://doi.org/10.1093/cid/ ciaa329.

  7. South AM, Diz D, Chappell MC. COVID-19, ACE2 and the cardiovascular consequences. Am J Physiol Heart Circ Physiol 2020;1-21. doi: 10.1152/ajpheart.00217.2020.

  8. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020. DOI: 10.1016/j.jacc.2020.03.031.

  9. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-91. doi: 10.1038/nature01326.

  10. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020;1-5. doi: 10.1515/cclm-2020-0188.

  11. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis [Internet]. 2020;(April):3-6. Available from: https://doi.org/10.1007/ s11239-020-02105-8.

  12. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016;8(8):959-70. DOI: 10.2217/imt-2016-002.

  13. Mei H, Hu Y. [Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19]. Chinese J Hematol 2020;41(03):185-191. doi: 10.3760/cma.j.issn.0253-2727.2020.0002.

  14. Vetta F, Vetta G, Marinaccio L. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A vicious circle. J Cardiol Cardiovasc Res 2020;1(2):1-12. DOI: JCCR-1(2)-0109.

  15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA J Am Med Assoc 2020;323(11):1061-9. doi: 10.1001/ jama.2020.1585.

  16. Li L Quan, Huang T, Wang Y Qing, Wang Z Ping, Liang Y, Huang T, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;(3):12. https://doi.org/10.1002/jmv.25757.

  17. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr 2020;14(January):247-50. doi: 10.1016/j. dsx.2020.03.013.

  18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):1-10. https:// doi.org/10.1016/S0140-6736(20)30183-5.

  19. Gao C, Wang Y, Gu X, Shen X, Zhou D, Zhou S, et al. Association between cardiac injury and mortality in hospitalized patients infected with avian influenza A (H7N9) virus. Crit Care Med 2020;48(4):451-8. doi: 10.1097/ CCM.0000000000004207.

  20. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Jangaard N, Hosbond S, et al. Clinical characteristics and outcomes of patients with myocardial infarction, myocardial injury, and non-elevated troponins. Am J Med [Internet] 2015;129(4):1-17. Available from: http://dx.doi. org/10.1016/j.amjmed.2015.11.006.

  21. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz 2020;10-2. doi: 10.1007/s00059-020-04909-z.

  22. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet] 2020;6736(20):1-9. Available from: http://dx.doi. org/10.1016/S0140-6736(20)30566-3.

  23. Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;1-7. doi: 10.1097/CM9.0000000000000744.

  24. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol [Internet] 2020;(April):1-6. Available from: http://www.ncbi.nlm.nih. gov/pubmed/32270559.

  25. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;(00):1-4. https://doi.org/10.1111/jth.14768.

  26. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018;378(4):345-53. DOI: 10.1056/NEJMc1805679.

  27. Yousif MHM, Dhaunsi GS, Makki BM, Qabazard BA, Akhtar S, Benter IF. Characterization of angiotensin-(1-7) effects on the cardiovascular system in an experimental model of Type-1 diabetes. Pharmacol Res [Internet]. 2012;66(3):269-75. Available from: http://dx.doi. org/10.1016/j.phrs.2012.05.001.

  28. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ 2020;3(March):3-8. DOI: 10.3785/j.issn.1008-9292.2020.03.03.

  29. Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial. Int J Antimicrob Agents 2020;(January). doi: 10.1016/j. ijantimicag.2020.105949.

  30. Keshtkar-Jahromi M, Bavari S. A call for randomized controlled trials to test the efficacy of chloroquine and hydroxychloroquine as therapeutics against novel coronavirus disease (COVID-19). Am J Trop Med Hyg 2020;00(0):1-2. doi: 10.4269/ajtmh.20-0230.

  31. Bauman JL, Tisdale JE. Chloroquine and hydroxychloroquine in the era of SARS-CoV2: Caution on their cardiac toxicity. Pharmacotherapy 2020;0(0):1-2. https://doi. org/10.1002/phar.2387.

  32. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir- ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;1-13. DOI: 10.1056/NEJMoa2001282.

  33. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020;0:1-3. https://doi.org/10.1093/ eurheartj/ehaa231.




2020     |     www.medigraphic.com